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Abstract
Background: Wolfram syndrome (WFS) is a rare, neurodegenerative disease that typically presents with childhood
onset insulin dependent diabetes mellitus, followed by optic atrophy, diabetes insipidus, deafness, and neurological
and psychiatric dysfunction. There is no cure for the disease, but recent advances in research have improved
understanding of the disease course. Measuring disease severity and progression with reliable and validated tools is
a prerequisite for clinical trials of any new intervention for neurodegenerative conditions. To this end, we
developed the Wolfram Unified Rating Scale (WURS) to measure the severity and individual variability of WFS
symptoms. The aim of this study is to develop and test the reliability and validity of the Wolfram Unified Rating
Scale (WURS).
Methods: A rating scale of disease severity in WFS was developed by modifying a standardized assessment for
another neurodegenerative condition (Batten disease). WFS experts scored the representativeness of WURS items
for the disease. The WURS was administered to 13 individuals with WFS (6-25 years of age). Motor, balance, mood
and quality of life were also evaluated with standard instruments. Inter-rater reliability, internal consistency reliability,
concurrent, predictive and content validity of the WURS were calculated.
Results: The WURS had high inter-rater reliability (ICCs>.93), moderate to high internal consistency reliability
(Cronbach’s α = 0.78-0.91) and demonstrated good concurrent and predictive validity. There were significant
correlations between the WURS Physical Assessment and motor and balance tests (rs>.67, p<.03), between the
WURS Behavioral Scale and reports of mood and behavior (rs>.76, p<.04) and between WURS Total scores and
quality of life (rs=-.86, p=.001). The WURS demonstrated acceptable content validity (Scale-Content Validity
Index=0.83).
Conclusions: These preliminary findings demonstrate that the WURS has acceptable reliability and validity and
captures individual differences in disease severity in children and young adults with WFS.
Background
Wolfram syndrome (WFS), also known as DIDMOAD
(diabetes insipidus, diabetes mellitus, optic atrophy, and
deafness), is an autosomal recessive neurodegenerative
disease that typically presents with childhood onset
insulin dependent diabetes mellitus. WFS disease is rare,
with an incidence of 1 in 770,000 of the general popu-
lation, and 1 in 150 of the population with insulin
dependent diabetes mellitus [1,2]. WFS is associated
with death by ages 30-50 [1-3], commonly due to re-
spiratory failure. Other symptoms have been reported,
including seizures, cognitive deficits, depression, blad-
der and bowel dysfunction and ataxia [3]. Although
recent advances have improved the understanding
of pathogenesis underlying the degenerative course
in WFS [3], several aspects of the natural history of
WFS are unclear. Measuring disease severity and pro-
gression with reliable and validated tools is a pre-
requisite for clinical trials of any new intervention for
neurodegenerative conditions.
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To this end, we developed the Wolfram Unified Rating
Scale (WURS) to measure the severity and individual
variability of WFS symptoms, with a particular focus on
the known neurodegenerative aspects of the disease.
This rating scale is based on established severity rating
scales for other neurodegenerative conditions, such as
Batten Disease, Parkinson disease and Huntington dis-
ease [4-6]. Such measures have proven to be critical for
comparing samples across studies and centers, for
understanding factors that influence disease severity and
disease characteristics, and for the evaluation of inter-
ventions [4,6,7].
In order to establish the WURS as a potentially useful
metric for disease severity and change in disease severity
over time, we focus on the subscales that are meant to
capture current symptom severity, with a particular em-
phasis on the neurological and neurodegenerative fea-
tures of the disease. We describe the basic psychometric
features of these scales, including inter-rater reliability,
concurrent, predictive and content validity in a relatively
small sample of WFS patients in the relatively early
stages of the disease process. These preliminary findings
support the reliability and validity of the current version
of the WURS and indicate its potential for use in future
larger and longitudinal studies.
Methods
Protocol
Testing of the WURS occurred at the Washington Uni-
versity School of Medicine Wolfram Syndrome Research
Clinic at the Pediatric Clinical Research Unit (PCRU),
St. Louis Children’s Hospital and Barnes-Jewish Hospital
at Washington University in St. Louis. Patients with
WFS were examined with the WURS, neurological and
physical examinations, and psychiatric questionnaires to
sample features thought to be affected by WFS. Blood
glucose levels of the individuals with WFS were moni-
tored and recorded by research personnel at various
points throughout the Wolfram Syndrome Research
Clinic. Informed consent from a parent for minor parti-
cipants or from adult participants was obtained prior to
participation in the research clinic. The study was
approved by the Human Research Protection Office
(HRPO) at Washington University in St. Louis.
Participants
WFS patients aged 6 to 25 were recruited through the
Washington University Wolfram Syndrome Registry
website. Inclusion criteria were the diagnosis of insulin
dependent diabetes mellitus and optic atrophy before
the age of 18 and/or genetic confirmation of a WFS1
mutation. Exclusion criteria were the patient being un-
aware of the diagnosis of WFS and advanced stage of the
disease, making travel and participation difficult for the
subject and/or family.
WURS development
The WURS was developed in the following stages:
1. A review of the WFS literature was conducted to
identify the most frequently reported symptoms of
the disease.
2. Experts in WFS were identified to provide feedback
on the WURS.
3. Initial psychometric properties were examined. The
WURS was compared to a variety of physical and
psychiatric assessments.
Stage 1
The WURS was modeled after the Unified Batten Dis-
ease Rating Scale (UBDRS) with the permission of the
Neuronal Ceroid Study Group [4,7-10]. Batten disease is
a neurodegenerative disease occurring in childhood that
shares many symptoms with WFS, including vision loss,
psychiatric abnormalities, and physical and neurological
decline [4]. The UBDRS was developed to quantify
symptom severity of Batten disease through ratings of
physical, neurological, and psychiatric impairments,
modeled on other standard clinical ratings scales for
neurodegenerative disorders, such as the Unified Parkin-
son Disease Rating Scale (UPDRS) [6] and the Unified
Huntington Disease Rating Scale (UHDRS) [5]. The
UBDRS has been demonstrated to have good inter-rater
reliability (ICCs = .68-.85) in studies of children with
Batten disease [4]. In addition, the UBDRS Behavioral
Assessment subscale has been cross validated with the
Achenbach Child Behavior Checklist, with rs ranging
from 0.39 to 0.72 with related items [8]. The UBDRS has
been used in studies to quantify decline in physical func-
tioning [9], measure change in disease severity over time
in longitudinal studies, to compare sex and genotype dif-
ferences [8,10], and to determine treatment efficacy [11].
Given the acceptable metrics and utility of the UBDRS,
and similar neurodegenerative features of Batten Disease
and WFS, we retained all of the original items of the
UBDRS for our first draft of the WURS. We then evalu-
ated the literature for WFS specific symptoms that were
not adequately covered by the UBDRS. On the basis of
these reports, we added items on hearing, bladder func-
tion, bowel function, temperature regulation, tandem
walking, and trunk stability [2]. Tandem walking was
added to the WURS based on the standards of the Phys-
ical and Neurological Examination of Subtle Signs
(PANESS) and Unified Huntington Disease Rating Scale
(UHDRS) [12,13].
In this final form, the WURS was divided into the
following subscales: Physical Assessment, Behavioral
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Assessment, Seizure Assessment, Capability Assess-
ment, and WFS history.
The Seizure Assessment contains a descriptive ques-
tionnaire about the presence and frequency of various
types of seizures experienced by the patient. Seizures are
common in Batten’s disease, and since seizures have
been reported in WFS, we elected to retain this section
of the UBDRS in the WURS. The Capability Assessment
contains 10 items in which parents rate their child’s abil-
ity to take part in school, chores, play, activities of daily
living, and chores. The individual is rated on capability
with these activities, including and excluding functional
impairment resulting from visual deficits. The WFS His-
tory section allows the rater to document the age of
onset of existing classical WFS symptoms and any add-
itional symptoms that are not listed.
We will report here on the two main subscales that
are meant to capture current severity of neurological
symptoms in WFS and thus are most suited for track-
ing changes over time: Physical Assessment (34 items
rated on a scale from 0 = no symptoms to 4 = high-
est severity; total score range = 0-136) and Behavioral
Assessment (9 items rated on frequency and severity
from 0 = normal behavior to 3 = highest severity;
total score range = 0-54). The Physical Assessment is
divided into two sections: One of which requires a
physician to rate the physical symptoms observed in
the patient, and the other in which the parent reports
the severity of their child’s symptoms that cannot be
physically examined to the physician. A total score is
generated through the summation of the Physical and
Behavioral Assessment scores (43 items, range = 0-
190). Individual items on the WURS Physical and Be-
havioral assessments are listed in Table 1. The Seizure
and Capability assessments will be examined in future
studies.
The WURS in its entirety takes approximately 20 min-
utes to complete. For this preliminary study, only
pediatric neurologists administered the exam. A training
manual modeled after the UBDRS training manual was
used to train the examiners.
Stage 2
Three content experts were chosen for their direct clin-
ical experience with WFS and additional expertise in
pediatric endocrinology (n = 1) or pediatric neurology
(n = 2). These experts provided qualitative feedback on
the organization, wording and format of the WURS.
Stage 3
Additional tests administered: Standard tests of phys-
ical, psychological, and neurological function were admi-
nistered for comparison with the WURS Behavioral and
Physical Scales in order to determine concurrent and
predictive validity.
Physical and Neurological Examination for Subtle
Signs (PANESS) The PANESS assesses the presence of
subtle neurologic signs in children through motor
assessments. The sum of the Gaits & Stations portion of
this assessment was used for our analyses and compared
to age and gender based norms. Higher scores indicate
greater severity with this assessment [12]. A pediatric
neurologist administered the assessment.
Mini-Balance Evaluation Systems Test (MiniBESTest)
The Mini BESTest is a clinician rated assessment of dy-
namic balance. Lower scores are indicative of impair-
ments in balance. The total possible score on this
evaluation is a 32, indicating no balance impairment
[14]. The assessment was administered by a physical
therapist.
Achenbach Child Behavior Checklist (CBCL) The
Achenbach Child Behavior Checklist is a parent reported
measure of aggressive behavior, anxiety, depression, at-
tention problems, defiant behavior, social problems,
somatic complaints, thought problems, and withdrawn
Table 1 WURS Domains and Items for Physical and Behavioral Assessments
WURS Domain Items Maximum Score
Physical – Physician Rated Speech Clarity, Abnormal Repetitive Speech Sounds, Tongue Protrusion,
Visual Acuity, Hearing, Passive Motion of Arms, Legs, and Neck,
Power of Arms and Legs, Hand Taps, Maximal Dystonia, Normal
Spontaneous Movements, Gait, Trunk Stability, Retropulsion Pull Test,
Heel Stomping, Motor Tics or Stereotypes, Myoclonus, Rest Tremor,
Tremor with Maintained Posture or Action, Dysmetria, Appendicular
Chorea, Tandem Walking
124
Physical – Parent Rated Temperature Regulation, Bladder Control, and Bowel Control 12
Behavioral – Parent Rated Sad Mood, Apathy, Anxiety, Aggression Toward Others, Aggression Toward
Self, Stereotyped/Repetitive Behaviors, Compulsions, Auditory Hallucinations,
and Obsessions
54
Total Score Sum of Physical and Behavioral Assessments 190
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behavior for ages 6 to 18. The CBCL Total Problems T
Score was used in analyses (higher T scores indicate
greater severity; borderline range = 60-64, clinical range
≥ 65 for Total T scores) [15].
Spence Children’s Anxiety Scale (SCAS) The Spence
Children’s Anxiety Scale is a self reported measure of
anxiety for ages 8 to 15. It contains questions categor-
ized into obsessive-compulsive problems, separation
anxiety, social phobia, panic, agoraphobia, fears about
physical injury, and generalized anxiety symptoms. T
scores were calculated based on existing norms; a higher
score indicates greater severity [16,17].
Pediatric Quality of Life Inventory, Generic Scales -
Parent Report Version 4.0 The PedsQLTM is a parent
reported survey for children and young adults with sub-
scales: Physical, Emotional, Social, and School Function-
ing [18]. The PedsQL Total score (sum of Physical and
Psychosocial items), Physical score (sum of items on
Physical subscale), and Psychosocial (sum of the Emo-
tional, Social, and School subscales) scores were calcu-
lated. Higher scores indicate higher quality of life.
Reliability
To test inter-rater reliability of the WURS, each patient
was assessed by two pediatric neurologists simultan-
eously. One neurologist directed the patients to perform
elements of the test and asked the parents questions for
both the Physical and Behavioral Assessments, and then
both neurologists scored the participants independently.
Inter-rater reliability of the WURS was determined
through calculation of intraclass correlation coefficients
for the Physical and Behavioral Assessments using mixed
models and absolute agreement. Internal consistency
reliability was determined through examination of
Chronbach’s α.
Content validity
Experts were asked to evaluate the WURS with a con-
tent validity form designed to calculate a Content Valid-
ity Index (CVI). Published guidelines were utilized to
create the content validity form [19-21]. Individual items
were rated on a scale of 1 to 4 to measure the perceived
‘representativeness’ of the Physical and Behavioral As-
sessment items to WFS. A score of 1 indicated that the
item was judged to be not representative of WFS, 2 indi-
cated that major revisions are recommended for the
item, 3 indicated that minor revisions are recommended
for the item, and 4 indicated that the item is representa-
tive of WFS and does not need revision.
The proportion of experts rating each item as relevant
(score of 3 or 4 on the content validity rating form) was
calculated for the Physical and Behavioral Assessments.
These values were then averaged to compute the Scale
Content Validity Index (S-CVI). Higher S-CVI values in-
dicate greater content validity.
Concurrent validity
The degree of concurrent validity between the WURS
and other physical and psychological variables was deter-
mined using Spearman’s correlations on the WURS
Total Score, WURS Physical Score, WURS Behavioral
Score, PANESS, Mini-BESTest, CBCL, and SCAS. Spear-
man’s correlations were used to determine validity due
to the ordinal rating scales utilized in all measures.
For each patient we calculated T scores on the CBCL
and SCAS, z scores on the PANESS using published
norms [12] and total scores on the Mini-BESTest. Spear-
man’s correlations were performed to determine how
these measures related to appropriate WURS subscales.
Predictive validity
In addition, total and domain scores were calculated for
the PedsQL. Spearman’s correlations were calculated be-
tween the WURS Total Scale and the PedsQL Total,
Physical, and Psychosocial scores to measure predictive
validity of the WURS for health related outcomes.
Results
Reliability
Eleven participants were assessed by both raters with
the WURS. Intraclass correlation coefficients (ICCs)
were excellent for all scales of the WURS (Physical
Rated ICC = 0.96, Physical Reported ICC = 0.93, Phys-
ical Total ICC = 0.97, Behavioral ICC = 0.97, and Total
ICC = 0.98). The Physical and Behavioral Assessments
on the WURS both had moderate to high internal
consistency reliability (Cronbach’s alpha coefficient;
Physical = 0.91; Behavioral = 0.78).
Content validity
The Scale Content Validity Index (S-CVI) was 0.83 for
the WURS Physical and Behavioral Assessments com-
bined. The minimum acceptable value for the S-CVI of
a measure is 0.80 [19].
Concurrent and predictive validity
Twelve participants were able to complete both the
WURS and motor and balance tests. WURS results are
Table 2 Median, Standard Deviation, and Range of scores
on the WURS
WURS Domain Median Min Max
Physical Assessment 5 0 29
Behavioral Assessment 3.5 0 14
Total Score 11.5 3 40
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reported in Table 2. Higher (more severely affected)
scores on the WURS Physical scale (but not the Behav-
ioral scale) correlated with poorer scores on the PANESS
and Mini-BESTest, but not the CBCL and SCAS (Table 3
and Figure 1A-D).
Z-scores on the PANESS ranged from -0.38 to 14.8,
with higher scores indicating greater impairment, while
raw scores on the Mini BESTest ranged from 12 to 32,
with lower scores indicating higher severity of symptoms.
Higher (more severely affected) scores on the WURS Be-
havioral Assessment (but not the Physical Scale) corre-
lated with higher (more severely affected) scores on the
CBCL and SCAS scales (Table 3 and Figures 1A-B). For
the CBCL, 2 of the 8 subjects scored within the clinical
or borderline range of severity. For the SCAS, 1 of the 8
subjects demonstrated elevated scores of anxiety. Higher
scores on the WURS Total Scale, indicating more sever-
ity of symptoms, also correlated with lower scores (more
severely affected) on the PedsQL (Table 3, Figure 1E).
Mean blood glucose levels taken during the study for
the individuals with WFS averaged 222.5 mg/dL (SD =
69.1 mg/dL, max = 312.5 mg/dL, min = 94 mg/dL). No
patients experienced any acute neurological symptoms
related to hypoglycemia or hyperglycemia during the
study.
Discussion
The findings of this study confirm the reliability and val-
idity of this version of the WURS and suggest that it
may be useful as a tool for assessing severity across
neurological, physical and behavioral domains in WFS.
The WURS demonstrates good inter-rater reliability and
internal consistency, supporting the potential utility of
the WURS across both clinical and research settings, in-
cluding clinical trials. Content and concurrent validity
were acceptable, as indicated by the high S-CVI values
and Spearman’s rho. This demonstrates that the current
version of the WURS is an accurate measure of many of
the key neurological aspects of WFS. In addition to con-
current validity, we also found that the WURS had good
predictive validity, in that it correlated with overall qual-
ity of life. Quality of life is considered to be the most im-
portant indicator of health outcomes in clinical practice
and research. It is also considered by the FDA to be the
most relevant outcome measure for clinical trials
[18,22,23]. Thus, these preliminary data suggest that the
WURS is capturing aspects of the disease that are im-
portant to an individual’s daily life and well-being.
The selective nature of the correlations between
WURS scales and conceptually similar standardized
measures also suggested that the Physical and Behavioral
scales capture qualitatively different constructs. For in-
stance, the WURS Physical Assessment correlated highly
with physical and neurological measures, but had low
correlations with psychiatric measures. The WURS Be-
havioral Assessment demonstrated high correlations
with measures of mood and behavior, and low correla-
tions with physical and neurological assessments.
Furthermore, results suggest that there is variability
within WFS for each construct that may be important to
capture. For example, some aspects of WFS may pro-
gress at a different rate than others, or be differentially
responsive to treatment. Thus, having valid, reliable
measurement tools for these different constructs may be
highly clinically relevant [20]. Longitudinal follow-up of
this cohort and a larger, more diverse sample will be ne-
cessary to determine whether this is true.
The WURS appears to be sensitive to relatively mild
stages of WFS. Our sample was small and tended to be
in the early stages of the disease, but still had some vari-
ation in duration and severity of symptoms. The WURS
captured this variability, distinguishing between mild
and moderate levels of severity. For instance, the range
of scores on the WURS Behavioral assessment (0 to 14
out of a possible 54) indicated that the individuals tested
had relatively subtle behavioral issues. Yet, these scores
correlated with ratings on the CBCL and SCAS, which
placed the majority of participants within the normal
range according to published norms. The mild levels of
severity of all assessments of mood and behavior, in
addition to the significant correlations between these
measures, demonstrate that the WURS Behavioral As-
sessment is a sensitive measure of mood and behavior
problems. The Mini-BESTest and PANESS, measures of
physical and neurological impairment, also correlated
highly with the WURS Physical Scale. Scores on these
assessments demonstrated low to moderate levels of im-
pairment indicating that this domain is also an accurate
and sensitive measure of physical impairment.
There are several limitations of this study, including
the small sample size, which is not uncommon in
Table 3 Intercorrelations among WURS and other measures of severity
Mini-BESTest (n=12) PANESS (n=12) CBCL (n=8) SCAS (n=8) PedsQL Total (n=10)
rs p rs p rs p rs p rs p
WURS Physical −0.69 0.01 0.67 0.02 0.31 0.46 0.41 0.36
WURS Behavioral −0.12 0.71 −0.10 0.77 0.77 0.03 0.80 0.03
WURS Total −0.54 0.07 0.45 0.14 0.62 0.10 0.69 0.09 −0.86 0.001
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clinical research studies of rare disease. Continued re-
search in this population across research centers, clinics
and countries using standardized assessments such as
the WURS will be necessary to draw stronger conclu-
sions. Given the now promising validity and reliability of
the WURS, we are now starting to establish such colla-
borations. In addition, time constraints limited us from
having both WURS raters independently administer and
score the WURS. To eliminate potential of bias by hav-
ing both raters in the same room, future studies should
implement independent administration and scoring of
the WURS. Despite this limitation, our method does
allow the conclusion that the current version of the
WURS can be used consistently across individuals when
they are provided with the same information.
Future modifications of the WURS are possible. For ex-
ample, the WURS currently lacks some reported symptoms
of WFS, including dysphagia, gag reflex impairment, per-
ipheral and autonomic neuropathy, and cranial nerve in-
volvement [24,25]. These items could be added to the
WURS Physical Assessment, which may be particularly
useful with more severely affected cohorts. Notably, there is
a part of the WURS that allows for symptoms not listed to














































































































Figure 1 Scatterplots of WURS scales vs. other measures: A) PANESS Gaits & Stations z-score and WURS Physical Scale (rs = 0.67,
p = 0.02) B) Mini-BESTest Total scores & WURS Physical Assessment (rs = -0.69, p = 0.01) C) CBCL Total T score and WURS Behavioral
Assessment (rs = 0.77, p = 0.03) D) SCAS Total T score and WURS Behavioral Assessment (rs = 0.80, p = 0.03) E) WURS Total & PedsQL
Parent Total Scores (rs = -0.86, p = 0.001).
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symptoms were noted. The WURS also includes items
from the UBDRS that are not as widely recognized as com-
mon WFS symptoms. At this stage of the WURS develop-
ment, we decided to keep all items from the UBDRS
because they were psychometrically sound, and we could
not be sure that the items would not be useful in more se-
verely affected patients. With greater use of the WURS
across time, a wider range of age and severity levels, we will
be able to perform item specific analyses and drop items
that have no added value for assessing disease severity and
change over time. Finally, with the exception of the WFS
History section, diabetes-related symptoms are not specific-
ally addressed in the WURS. It is thought that these symp-
toms are not degenerative after diagnosis, unlike those of
the neurological aspects of disease. However, exploration of
diabetes-related symptoms may be necessary for a better
understanding of diabetes treatment issues. Appropriate-
ness of diabetes related items will be considered for the
WURS once further examination is completed. Import-
antly, there are existing validated questionnaires for dia-
betes complications, management and quality of life that
could be used as adjunct measures to the WURS if desired
[26-29]. Similarly, cognitive testing is not currently incorpo-
rated into the WURS. While cognitive impairment has
been reported in advanced WFS, it has not been found with
standard assessments in our small sample of early WFS
patients [30]. Further assessment will determine if cognitive
items should be added to the WURS, or if the result of a
supplementary cognitive test should be reflected in the
WURS scoring.
Although neurologists are currently the primary clini-
cians using the assessment, it is hoped that other health
care practitioners will be able to administer the WURS
effectively. A training video will be developed in the
future. We will investigate the minimum amount of
training necessary for neurologists or other health pro-
fessionals to administer the WURS. The UPDRS and
other similar ratings scales are typically given by a var-
iety of health professionals and technicians, who follow
standardized training.
In summary, the preliminary data presented here sup-
port the use of the WURS in studies of WFS as a reli-
able and valid measurement tool for disease severity.
The scale will continue to be developed as we are able
to test a larger and more diverse sample. Further devel-
opment and analyses of the WURS will be important for
continued research of WFS in order to better under-
stand symptoms and progression of the disease, in
addition to its eventual use in clinical trials for thera-
peutic interventions.
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